Patent ductus arteriosus (PDA) remains a prominent clinical challenge in the management of preterm infants. During fetal life, the ductus arteriosus diverts blood away from the underdeveloped lungs, ...

Active treatment of hemodynamically significant patent ductus arteriosus (PDA) in preterm infants within the first 2 weeks of life was associated with worse outcomes than expectant management.

“This position statement represents a collective effort between neonatology, anesthesia, and interventional cardiology to provide comprehensive guidance on tcPDA device occlusion that can be adapted ...

The multicentre, randomised, double-blind, placebo-controlled Baby-OSCAR trial. Participants were 653 extremely preterm infants with a large patent ductus arteriosus (diameter, ≥ 1.5 mm). In the first ...

Italy: A new study published in Pediatric Research has questioned the long-standing practice of fluid restriction in preterm ...

Merit Medical Systems initiates a study to evaluate the Bloom Micro Occluder System for treating patent ductus arteriosus in premature infants. Merit Medical Systems, Inc. has announced the enrollment ...